Last updated 26 days ago
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
320 patients around the world
Available in Puerto Rico, Argentina, United States
Eli Lilly and Company
10Research sites
320Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 2
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CEDIMBA - DIM Clínica Privada - Buenos Aires
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Centro Médico Viamonte SRL - CABA, Buenos Aires
Centro de Investigaciones Médicas Mar del Plata SRL
Investigaciones Médicas IMOBA SRL
CEDIC Centro de Investigación Clínica - CABA, Buenos Aires
Instituto de Investigaciones Clínicas Zárate
Instituto de Investigaciones Clínicas de Rosario
Centro Médico Colón
Centro Médico Cimel Chahin Chahin S.A.
SponsorEli Lilly and Company
Conditions
Diabetes mellitus type 2
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06297603
